5 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
7d
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Top Analyst Reports for Mastercard, UnitedHealth & Merck http://www.zacks.com/research-daily/610256/top-analyst-reports-for-mastercard-unitedhealth-merck?cid=CS-ZC-FT-research_daily-610256 Nov 08, 2019 - Top Analyst Reports for Mastercard, UnitedHealth & Merck
The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health http://www.zacks.com/stock/news/614373/the-zacks-analyst-blog-highlights-mastercard-unitedhealth-merck-qualcomm-and-cvs-health?cid=CS-ZC-FT-press_releases-614373 Nov 11, 2019 - The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health
Novartis' Generics Unit to Buy Aspen's Japanese Operations http://www.zacks.com/stock/news/614127/novartis-generics-unit-to-buy-aspens-japanese-operations?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-614127 Nov 11, 2019 - Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.
Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review http://www.zacks.com/stock/news/615678/bristol-myers-opdivo-yervoy-sbla-for-hcc-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-615678 Nov 12, 2019 - Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes http://www.zacks.com/stock/news/619673/fda-panel-votes-against-lillys-jardiance-for-type-i-diabetes?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-619673 Nov 14, 2019 - Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

Pages: 1

Page 1